Whole HIV-1 genome sequences are pivotal for large-scale studies of inter-and intrahost evolution, including the acquisition of drug resistance mutations. The ability to rapidly and cost-effectively generate large numbers of HIV-1 genome sequences from different populations and geographical locations and determine the effect of minority genetic variants is, however, a limiting factor. Next-generation sequencing promises to bridge this gap but is hindered by the lack of methods for the enrichment of virus genomes across the phylogenetic breadth of HIV-1 and methods for the robust assembly of the virus genomes from shortread data. Here we report a method for the amplification, next-generation sequencing, and unbiased de novo assembly of HIV-1 genomes of groups M, N, and O, as well as recombinants, that does not require prior knowledge of the sequence or subtype. A sensitivity of at least 3,000 copies/ml was determined by using plasma virus samples of known copy numbers. We applied our novel method to compare the genome diversities of HIV-1 groups, subtypes, and genes. The highest level of diversity was found in the env, nef, vpr, tat, and rev genes and parts of the gag gene. Furthermore, we used our method to investigate mutations associated with HIV-1 drug resistance in clinical samples at the level of the complete genome. Drug resistance mutations were detected as both major variant and minor species. In conclusion, we demonstrate the feasibility of our method for large-scale HIV-1 genome sequencing. This will enable the phylogenetic and phylodynamic resolution of the ongoing pandemic and efficient monitoring of complex HIV-1 drug resistance genotypes.
N ext-generation sequencing (NGS) provides unprecedented possibilities for the large-scale sequencing of virus genomes. The sequencing of RNA viruses such as human immunodeficiency virus type 1 (HIV-1) depends on reverse transcription (RT) and amplification to enrich virus genomes to the amounts of DNA required for NGS. Furthermore, short-read sequence assemblies of RNA virus and HIV-1 genomes are complicated by the high level of population diversity (17) due to error-prone RNA polymerases and reverse transcriptases, respectively, and high rates of virus genome replication.
HIV-1 is one of the most genetically diverse viruses known. Four genetic groups have been described: the major group M, which causes ϳ85% (7) of the ϳ34 million infections worldwide (13a) and is further divided into nine subtypes (subtypes A to D, F to H, J, and K) (15) ; the outlier group O (3, 6, 31) ; the nonmajor and nonoutlier group N (28) ; and another recently designated group, group P (23) . Up to 35% amino acid differences between subtypes are found, and strains belonging to the same subtype can vary by up to 20% (7) . In addition, intersubtype recombination is common (25) . Circulating recombinant forms (CRFs), found in three or more epidemiologically unlinked individuals, and unique recombinant forms (URFs), identified in fewer than three individuals, consist of mosaic genomes with sections of two or more subtypes. To date, 51 CRFs have been identified.
The ability to generate HIV-1 genome sequences is crucial for an understanding of the dynamics of the pandemic at the population level and viral diversification, including the acquisition of drug resistance mutations, in individual patients. As the phenotype of a virus is the compound effect of polymorphisms present in a genome and as HIV therapy now targets proteins encoded by genes dispersed throughout the 9.7-kb genome, there is a need for high-performance HIV-1 whole-genome sequencing. A method for NGS of HIV-1 genomes of subtype B and analysis of minor variants was described recently (8) , but due to the remarkable degree of sequence heterogeneity, a universal method for the generation of large numbers of HIV-1 genome sequences has remained elusive.
Here we present a novel method for rapid and reliable amplification, NGS, and the assembly of HIV-1 genomes that does not necessitate prior knowledge of the HIV-1 group or subtype. We apply the method to investigate the genetic diversity of HIV-1 genes, groups, and subtypes as well as mutations associated with HIV-1 drug resistance in clinical samples. Table S1 in the supplemental material). Viral RNA was purified with a QIAamp viral RNA minikit (Qiagen).
MATERIALS AND METHODS
Primer design and one-step RT-PCR. A "pan"-HIV-1 primer set for the amplification of HIV-1 genomes of all groups and subtypes was designed based on 1,496 sequences of the 2009 "Web alignment" from the Los Alamos HIV Sequence Database (Table 1) . One-step RT-PCRs generating overlapping amplicons of 1.9 kb, 3.6 kb, 3 kb, and 3.5 kb were performed by using a SuperScriptIII One-Step RT-PCR system with Platinum Taq DNA High Fidelity polymerase (Invitrogen). Each 25-l reaction mixture contained 12.5 l reaction mix (2ϫ), 4.5 l RNase-free water, 1 l each of each primer (20 pmol/l), 1 l SuperScriptIII RT/ Platinum Taq High Fidelity mix, and 5 l of template RNA. Cycling conditions were 50°C for 30 min; 94°C for 2 min; 35 cycles of 94°C for 15 s, 58°C for 30 s, and 68°C for 4 min 30 s; and, finally, 68°C for 10 min. Amplicons were verified by agarose gel electrophoresis and quantified by using Quant-iT PicoGreen dsDNA reagent (Invitrogen).
Roche/454 sequencing, quality control, and read assembly. Amplicons were pooled in equimolar amounts, and 500 ng of DNA was sequenced by using a Genome Sequencer FLX Titanium XL ϩ instrument (Roche/454 Life Sciences) (19) . Up to 17 samples were sequenced on one-quarter of a PicoTiterPlate using multiplex identifier (MID) adaptors, as previously described (4) . SFF files were de-multiplexed and converted to FASTQ files, primer sequences were removed, and quality control (removing reads of Ͻ200 bp and trimming low-quality bases from the 3= end of the reads until the median quality of the read was Ͼ30) was performed by using QUASR (http://sourceforge.net/projects/quasr/). A de novo assembly was constructed by using GS De Novo Assembler, version 2.6 (Roche/454 Life Sciences). Overlapping contiguous sequences were aligned by using CAP3 (11) and visually inspected with Se-Al, version 2.0a11 (http://tree.bio.ed.ac.uk/software/seal/), to derive a consensus sequence.
Phylogenetic analysis. A reference set of 29 full-genome sequences was obtained. A total of 25 representative HIV-1 sequences from each group and subtype, 2 simian immunodeficiency virus (SIV) SIV cpz sequences, and 2 SIV gor sequences were selected. The sequences have the following GenBank/EMBL/DDBJ accession numbers: AB253421, AB287379, K03455, AY423387, EF469243, AB254141, K03454, DQ054367, U54771, AB253423, FJ771010, AB485658, AF084936, AY612637, AF190127, FJ711703, GU237072, AF082394, AJ249235, AJ249239, L20571, AJ302647, AJ006022, AJ271370, GU111555, DQ373066, AF103818, FJ424866, and FJ424863. Sequences derived in this study were aligned with the reference set by using MAFFT, version 6.857b (14) , and the alignment was manually curated. A Bayesian phylogeny was reconstructed by using MrBayes, version 3.2 (12) , under the general timereversible model of nucleotide substitution with the proportion of invariable sites and gamma-distributed rate heterogeneity, as determined by jModelTest, version 0.1.1 (24) . The Markov chain Monte Carlo search was set to 50,000,000 iterations, with trees being sampled every 2,500th generation and a 20% burn-in being discarded. Multiple chains were run to check chain convergence. The tree was edited with FigTree, version 1.3.1 (http://tree.bio.ed.ac.uk/software/figtree/).
Detection of HIV-1 subtypes and recombination. The Rega HIV-1 Subtyping Tool, version 2.0 (http://dbpartners.stanford.edu/Rega Subtyping/), and the Recombinant Identification Program, version 3.0 (http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html), were used to identify the subtypes of sequences and the presence of recombinants. Recombination was verified with the manual bootscan method (27) , implemented in the Recombination Detection program, version 3.42 (20, 21) .
Visualization of HIV-1 genome diversity. Circos software (16) was used to visualize the diversity of HIV-1 genes, groups, and subtypes.
Drug resistance mutations. The consensus sequence for each sample was used as a sample-specific reference sequence for the mapping of reads using Burrows-Wheeler Aligner (18) . To analyze minor species, read depth and frequencies of mutations associated with drug resistance, as outlined in the Stanford HIV drug resistance database (http://hivdb .stanford.edu/), were calculated by using custom Python scripts.
Nucleotide sequence accession number. The Roche/454 Life Sciences sequencing data obtained in this study are available from the EMBL/GenBank/DDBJ Sequence Read Archive under study accession number ERP001257.
RESULTS AND DISCUSSION
Design of a protocol for pan-HIV-1 RT-PCR, NGS, and assembly of HIV-1 genomes. We designed a "pan"-HIV-1 primer set targeting semiconserved regions of the genome, based on ϳ1,500 HIV-1 genome sequences (Table 1 ; see also Fig. S1 in the supplemental material). This novel primer set reverse transcribes and amplifies the amino acid coding region and partial long terminal repeats (LTRs) of the HIV-1 genome in four overlapping products. We chose a one-step RT-PCR protocol and a MID-tagged library preparation to minimize sample handling and to enable the processing and potential automation of large numbers of samples. We did not apply the primer ID approach that addresses the problems of resampling, PCR error and recombination, differential amplification, and sequencing errors (13) , as it cannot be adapted easily to a one-step RT-PCR protocol using long amplicons. It is important to sequence the viral RNA genome and not the proviral DNA, as the former represents the current replication pool contributing to HIV-1 diversity and evolution. We combined our pan-HIV-1 RT-PCR method with Roche/454 sequencing and de novo virus genome assembly, as the reference genomebased assembly introduces biases (2) . Therefore, our new method can be adapted readily to other RNA viruses as primer sets (34) or algorithms to design them (33) become available. We estimate the cost of sequencing reagents to be $270 per sample, if 100 samples are sequenced on a PicoTiterPlate to achieve a minimum coverage of 500-fold to identify minor species, and Roche/454 list prices are applied. Broad application of the protocol. As a first step, we used the WHO HIV-1 genotype reference panel (10) to validate our primer set. The panel comprises 10 RNA samples of HIV-1 groups M, N, and O and various subtypes, and we successfully amplified all four products from each sample (see Fig. S2 in the supplemental material). An in silico PCR was performed by using the 468 HIV-1 genome sequences in GenBank of sufficient length to cover all primer sites (Ն9,300 bp) to investigate computationally the function of the primer set across a broad range of HIV-1 diversities (see Fig. S3 in the supplemental material). This virtual PCR showed that the primer set could successfully amplify full genomes from 394 (84%) of these viruses, while 74 (16%) failed to bind at least one primer and would not be expected to yield full genome coverage.
As a second step, we reverse transcribed, amplified, and sequenced 15 RNA samples of various HIV-1 groups and subtypes as well as CRFs, ranging from cell culture reference subtype virus strains to primary clinical isolates to uncultured EDTA plasma virus samples. Virus strains were selected to be representative of the HIV-1 diversity spectrum, and rare subtypes/groups were also included, while primary isolates and plasma virus samples were randomly selected. Short-read data were preprocessed by using QUASR (http://sourceforge.net/projects/quasr/), and de novo genome assemblies were performed. For all samples, the complete amino acid coding region of the HIV-1 genome was covered. Sequences of all major subtypes of group M, as well as groups N and O, were generated by NGS. Bayesian phylogenetic analysis of 14 assembled HIV-1 genomes (not including CRF14_BG) together with a reference set of complete HIV-1 and SIV genomes showed that NGS and assembly were successful across the range of HIV-1 diversities (Fig. 1) . Previously sequenced HIV-1 strains were included in the analysis. GenBank sequences and sequences obtained by NGS showed nucleotide identities of 98.8 to 99.4% (see Table S1 in the supplemental material). As expected, a clear phylogenetic clustering of GenBank sequences and sequences obtained by NGS was found for both strain 5 (group N) and strain 6 (group O). The minimal differences reflect accumulated genetic variations from cultures of these HIV-1 strains since their original isolation. We also sequenced two CRFs, CRF01_AE and CRF14_BG and used the derived HIV-1 genomes to verify recombination (see Fig. S4 in the supplemental material). The ability to amplify and sequence CRFs using one set of pan-HIV-1 primers is of central importance, as CRFs play a significant role in regional epidemics and new CRFs continue to emerge (7, 30) .
Specificity. For specificity tests, we used RNA or DNA from plasma samples of patients infected with other blood-borne viruses important for the differential diagnosis of HIV-1 and samples from healthy individuals. All samples, including nucleic acid obtained from plasma samples positive for HIV-2, cytomegalovirus, and hepatitis C virus, with various viral loads, failed to amplify the HIV-1 PCR products (see Table S1 in the supplemental material).
Sensitivity. The sensitivity of the RT-PCR was determined by using a total of 90 plasma virus samples of known copy numbers, ranging from 3,000 to 2,800,000 copies/ml (see Fig. S5 in the supplemental material). We were able to amplify all four products from 84/90 samples (93.33%) and determined a sensitivity of at least 3,000 copies/ml. For the remaining 6 samples (6.66%) that did not have specifically low viral loads, we successfully amplified three products. This sensitivity of 3,000 copies/ml is sufficient for many samples, but a higher sensitivity would be preferred for clin-ical utility. Nevertheless, there is the possibility of extracting RNA from a larger volume of plasma if the detection limit of the protocol described here is reached.
Reproducibility and accuracy. To investigate the reproducibility and accuracy of our method, we repeated both emulsion PCR and sequencing runs for the complete set of 15 samples, using the Roche/454 libraries as starting material. The consensus sequences that were derived were 100% identical to the consensus sequences generated by the first sequencing run (see Table S1 in the supplemental material). The frequency of mutations associated with drug resistance in clinical samples differed by a maximum of 1.1% ( Table 2 ). The clinical impact of these minor species is as yet undetermined, but they can represent a reservoir for the emergence of resistant viruses (32) . While the exact frequencies of minor species are clearly of research interest, mutations that imply drug resistance should be considered, regardless of their frequencies.
Frequency of in vitro recombination. To determine the frequency of in vitro recombination and the accuracy of frequencies of minor species, we prepared a 1:1 mix of RNA from two plasma samples containing HIV-1 subtype B (viral load, 360,000 copies/ ml) and subtype C (viral load, 120,000 copies/ml), respectively. We amplified one amplicon from this mixed population using primer set 1, endpoint diluted the amplicon, and reamplified it in 96-well plates so that fewer than 20% of the wells yielded a product (26) . We sequenced 64 reamplified products separately and included amplicons derived from the nonmixed RNA of subtypes B and C as controls. For each sequence, we determined the subtype and controlled for recombination. We found 46/64 (71.88%) products of subtype B, 17/64 (26.56%) products of subtype C, and a single product with an intersubtype B-C recombinant sequence corresponding to an in vitro recombination rate of 1.56% (see Table S2 in the supplemental material). Therefore, both in vitro recombination and differential amplification did not represent a major problem when this protocol was applied. However, in vitro recombination can occur during PCR amplification and depends on various factors such as the amount of template DNA and the specific PCR conditions (22) . NGS deep-sequencing studies need to take into account and aim to minimize in vitro recombination, as it can be mistaken for viral recombination or lead to an overestimation of the viral diversity. Genetic diversity of HIV-1 genes, groups, and subtypes. To further validate our method, we compared and visualized the genetic diversities of HIV-1 in different genes and between groups and subtypes ( Fig. 2 ; see also Fig. S6 in the supplemental material). We found variation across the genome sequences where we expected it, and all open reading frames were maintained. The sequence similarities of different HIV-1 groups and subtypes to subtype B reference strain HXB2 were particularly low in the env, nef, vpr, tat, and rev genes and parts of the gag gene, while the pol gene showed the highest level of intersubtype similarity. These results are consistent with a previous study that obtained a comprehensive map of positive selection as well as functional and structural constraints of the HIV-1 subtype B genome (29) . The group O and N sequences differed most from subtype B reference strain HXB2 and are shown relative to the relevant reference sequence in Fig. S6 in the supplemental material. Large-scale HIV-1 genome sequencing applying our new method will enable the combined analysis of host and viral genetic information for the range of HIV-1 subtypes.
Mutations associated with HIV-1 drug resistance. Highly active antiretroviral therapy is one of the most potent selective pressures on the HIV-1 genome. We used our method to investigate mutations associated with drug resistance in clinical samples ( Table 2 ). Rigorous quality control was performed so that the median quality score of each read was Ͼ30, corresponding to a base call accuracy of 99.9%. We suggest that a minimum average coverage of 500-fold is necessary for the reliable identification of minor species, as a cutoff of 1% (5/500 reads) was used for the lowest frequency of a variant to be considered genuine. This level is conservatively well in excess of the next-generation sequencing error rate of 0.1% (1, 4) . Between 40 (88.8%; plasma sample 4) and 44 (97.7%; plasma sample 1) of the 45 positions of interest were sequenced at Ͼ500-fold coverage. While drug resistance mutations were present in two plasma virus samples as the major variant (i.e., the consensus sequence), additional minor species with frequencies of between 1% and 46.9% were also identified at various positions. In contrast, HIV-1 strain 92UG037, which was included as a control, exhibited only minority D67N or K219Q/E mutations. These are secondary thymidine analogue mutations that occur in untreated populations (5) . We expect that the costeffective monitoring of complex drug resistance genotypes will be most efficiently achieved by NGS of complete HIV-1 genomes, as current antivirals target the HIV-1 protease, reverse transcriptase, integrase, and envelope (gp41), and CCR5/CXCR4 tropism needs to be considered as well.
In conclusion, we demonstrate the feasibility and the potential for large-scale HIV-1 genome sequencing from the range of HIV-1 genetic groups and subtypes prevalent globally. We expect that this new method will be pivotal for large-scale studies of the ongoing inter-and intrahost evolution of HIV-1. It has the potential to set a new standard for the clinical management of HIV infection by combining the detection of minor drug resistance mutations of clinical significance as well as covering gene targets of all present and future drug classes across the entire HIV-1 genome.
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